Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON24467

Enrollment

Registered

2016-03-31

Start date

2016-04-08

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic prostate cancer

Interventions

Repeated blood drawns and urine collection

Eligibility

Inclusion criteria

Inclusion criteria: - Histologically or cytologically confirmed adenocarcinoma of the prostate. - Measurable metastatic lesion(s) according to PCWG2 and/or RECIST 1.1 criteria - Intention to start (new) line of systemic treatment - Written informed consent - Willingness and capacity to follow the protocol specified visits for blood sampling for the total duration of the study. - Age ≥ 18 years. - WHO performance status ≤2. - Concurrent participation in CPCT-02 study

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
The rate of mPC patients with quantifiable ctDNA taken pre-treatment.	—

Secondary

Measure	Time frame
- The percentage of blood samples with sufficient ctDNA. - The interval between detected ctDNA and PSA response during treatment. - The correlation between ctDNA response and progression-free survival.	—

Contacts

Public ContactL.F. van Dessel

afdeling Interne Oncologie - Erasmus MC Kanker Instituut, kamer Be-414a

E-mail: l.vandessel@erasmusmc.nlTel.: 010-7044375

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)